CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 10, 2020-- Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will host a live webcast on

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Monday, February 3,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2020-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Thursday, January 2,

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 23, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at

Three poster presentations highlight the role of NMDA receptor dysfunction in Huntington’s Disease related cognitive impairment and potential for positive cognitive effects with SAGE-718 CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 10, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical

MOUNTAIN Study did not meet primary endpoint at Day 15 Statistical significance on HAM-D scale achieved at Days 3, 8 and 12; preliminary data from long-term follow-up suggest maintenance of effect on depressive symptoms Statistical significance achieved at Days 3, 8, 12 and 15 in patients with

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 3, 2019-- Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on Monday, December 2,

ZULRESSO™ (brexanolone) CIV injection revenues of $1.5M in third quarter Enrollment completed in SAGE-217 Phase 3 MOUNTAIN and SHORELINE studies with topline data expected in 4Q 2019 and 2020, respectively Planning to expand pipeline with two new GABA and NMDA clinical-stage assets Conference call

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 11, 2019-- Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will present at

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that on November 1, 2019 , the